India Engages In Quiet Covaxin Diplomacy; Likely To Get Approval In Several More Countries In Next Two Months

by Swarajya Staff - Jul 5, 2021 12:37 PM
India Engages In Quiet Covaxin Diplomacy; Likely To Get Approval In Several More Countries In Next Two MonthsBrazilian President Jair Bolsonaro with Prime Minister Modi (Image Via Twitter) 

In a significant boost for the approval of India's home-grown Covid-19 vaccine, Covaxin, the central government is reportedly engaged in quiet diplomacy to assist Bharat Biotech's vaccine to get an international nod.

Notably, Covaxin has already been approved by around 15 countries around the world, and the said move may result in approvals for the vaccine by several countries during July-August.

The report further added that, unlike China, India is engaged in quiet diplomacy. The Centre has advised Bharat Biotech on navigating the complex world of geo-economics transparently and through submission of data at global institutions and various world capitals.

Hyderabad-based Bharat Biotech India Ltd recently publicised the long-awaited results of the Phase-3 trial of Covaxin. The trial involved nearly 25,800 volunteers spanning 25 hospitals across India. It showcased 93.4 per cent effectiveness against severe COVID-19 disease, as per the results of the Phase-3 test.

Bharat Biotech has applied for regulatory approvals in more than 50 countries and emergency use listing with WHO Geneva.

"Bharat Biotech has now received approvals from more than 15 countries, with approvals from several additional countries to be received during July-August 2021. Now that results from Phase-III final analysis have been published, more countries from Asia, Africa, Latin America, Europe and North America have come forward to grant EUAs for Covaxin," the person quoted a person familiar with the development.

"During such a devastating pandemic it is morally and ethically reprehensible that countries place arbitrary and unilateral restrictions on travel. It is extremely important that countries mutually accept regulatory systems and medicinal products to encourage a quicker return to normalcy and restoration of lives and livelihoods. During the early days of the pandemic, several categories of medicines manufactured in India were accepted by countries worldwide, a similar note of reciprocity is the need of the hour," pointed out a source.

Get Swarajya in your inbox everyday. Subscribe here.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber
Get Swarajya in your inbox everyday. Subscribe here.

Latest Articles

    Artboard 4Created with Sketch.